| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3301104af41b545a7f2f35db8f763452 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08 |
| filingDate |
2019-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f68f8bc247ca4a9722f3d1a462e72f92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_105a3514793e15d26d8e762af5212c47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_906d7c74ad860a5763baca0db8bcd36e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fb5517b820f8c5839c9612a34208041
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67e413c9f5521f4752e776096559f399 |
| publicationDate |
2020-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202019880-A |
| titleOfInvention |
Compound as neurokinin-1 receptor antagonist and its use |
| abstract |
The present invention relates compounds of Formula (A) as NK-1 receptor antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to NK-1 receptor in humans. More specifically, the compounds and / or pharmaceutical compositions of the present invention are believed to potentially offer therapeutic benefits to patients who suffer, among others, chemotherapy-induced nausea and vomit (CINV) and / or post-operative nausea and vomit (PONV). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11400065-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11602512-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11602513-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11504347-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11766418-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11779557-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11583510-B1 |
| priorityDate |
2018-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |